Lineage Cell Therapeutics, Inc.: updates and filings

LCTXAMEXHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.77

November 20, 2026Market cap $192M

What Ploutos Investor adds for Lineage Cell Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($0.99 then, $0.77 on Nov 20, 2026). The figures date from before that move.10-Q
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 78 daysAround Feb 8, 2027 · for Q4 2026

last Aug 6, 2026next Feb 8, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 12, 2026Material agreement entered, acquisition or disposal of assets, results of operations, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations
    Form8-K
  • Jul 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jun 12, 2026Shareholder vote, other material events
    Form8-K
  • May 12, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Results of operations
    Form8-K
  • Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 23, 2026Filing
    FormEFFECT
  • Mar 19, 2026Correspondence with the SEC
    FormCORRESP
  • Mar 16, 2026Letter from the SEC
    FormUPLOAD
  • Mar 11, 2026Shelf registration for future offerings
    FormS-3
  • Mar 11, 2026Other material events
    Form8-K
  • Mar 5, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 5, 2026Results of operations
    Form8-K
  • Nov 28, 2025Other material events
    Form8-K
  • Nov 24, 2025Other material events
    Form8-K
  • Nov 14, 2025Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Nov 12, 2025Other material events
    Form8-K
  • Nov 6, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Nov 6, 2025Results of operations
    Form8-K
  • Sep 26, 2025Over-5% holder statement (passive)
    FormSCHEDULE 13G

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 17, 1996.

The full analysis

What do Lineage Cell Therapeutics's filings show?

The filings are where every one of Lineage Cell Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.